The global Intravenous Immunoglobulin market size was estimated at USD 11.9 billion in 2021 and is expected to surpass around USD 21.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.3% during the forecast period 2022 to 2030.
Overview of Intravenous Immunoglobulin Market
Immunoglobulins are highly purified, sterile-specific medical therapy solutions containing gamma globulin G (IgG) in a concentration of 95% or more. These are manufactured from a highly refined pool of human plasma collected from at least 100 donors or more. Immunoglobulins can be administered through three different routes such as intramuscular, intravenous, and subcutaneous. The intramuscular route of administration is a relatively older method and is not preferred presently, as it is painful. Intravenous immunoglobulin has emerged as a boon in the last few decades for patients with compromised immune systems.
Report Scope of the Intravenous Immunoglobulin Market
Report Coverage |
Details |
Market Size |
USD 21.7 Billion by 2030 |
Growth Rate |
CAGR of 8.3% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
And Geography, |
Companies Mentioned |
|
Rise in R&D Activities in Intravenous Immunoglobulin To Fuel Market Growth
Increasing adoption of immunoglobulin, along with a surge in frequency of product launches and prompt approval from government regulatory bodies across the world is expected to fuel the demand during the forecast period. According to an October 2020 update by the National Institutes of Health, a clinical trial to test the safety, tolerability, and efficacy of a combination treatment regimen for coronavirus disease 2019 (COVID-19) consisting of the antiviral Remdesivir plus, a highly concentrated solution of antibodies that neutralize SARS-CoV-2, the virus that causes COVID-19, was initiated in 2020. The study was performed on hospitalized adults with COVID-19 in the U.S., Mexico, and 16 other countries on five continents.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and funded the phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC. The antibody solution that was tested in the ITAC trial is anti-coronavirus hyperimmune intravenous immunoglobulin or hIVIG. Moreover, the rise in the number of government initiatives supporting the usage of the intravenous mode of delivery for some medications propels the global market. For instance, in June 2021, the Ministry of Health and Family Welfare of Karnataka, India, decided to procure an intravenous immunoglobulin (IVIG) drug worth more than INR 10 Cr for emergency use among children.
Surge in incidence of Primary Immunodeficiency Diseases to Drive Global Market
In terms of indication, the global intravenous immunoglobulin market has been classified into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. The hypogammaglobinemia segment dominated the global market in 2021. This can be attributed to increase in incidence of primary immunodeficiency diseases (PID) across the globe. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).
Preference for Hospital Treatment to Propel Demand for Intravenous Immunoglobulin in Hospitals
Based on end-user, the global intravenous immunoglobulin market has been divided into hospitals, clinics, and home care. The hospitals segment dominated the global intravenous immunoglobulin market in 2021, owing to rise in the number of patients opting for hospital treatment rather than standalone clinics. Moreover, patients receiving IVIG infusions at home have improved quality of life, as they get better control over day-to-day activities. For instance, IVIG infusions at home care have reduced scheduling clashes for patients.
COVID-19 Pandemic to Fuel Growth of Intravenous Immunoglobulin Market
The COVID-19 pandemic in its later phase is more likely to propel the growth of the global intravenous immunoglobulin market. December 2020 published article titled, 'COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience', stated that out of 100 individuals with primary immunodeficiency (PID), symptomatic secondary immunodeficiency (SID), autoinflammatory diseases, and C1 inhibitor deficiency, 72% were infected with the SARS-CoV-2 virus and 59% were admitted to hospitals, with 8% admitted to intensive care units. Therefore, an increase in immune-deficient individuals who are at higher risk of being infected with COVID-19 is likely to propel the global intravenous immunoglobulin market during the pandemic.
According to an October 2020 published article titled, 'The uSAGE of Intravenous Immunoglobulin Gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial', the administration of intravenous immunoglobulin in patients with severe COVID-19 infection was expected to enhance the clinical outcome and aid in a significant reduction of the mortality rate due to SARS-CoV2 viral infection. Hence, the global market is likely to witness strong growth during the pandemic.
Analysis of Key Players in Global Intravenous Immunoglobulin Market
This report profiles key players in the global intravenous immunoglobulin market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global intravenous immunoglobulin market is highly fragmented, with the presence of several international as well as regional players. Leading players operating in the global intravenous immunoglobulin market are Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V., among others.
The growing burden of target diseases such as primary immunodeficiency diseases is expected to fuel the growth of the market in the region. According to the National Institute of Allergy and Infectious Diseases, in 2020, more than 400 types of PIDs were diagnosed in the U.S., with more than 500,000 people affected by PIDs.
According to the USIDNET Registry, 2020, the frequency of severe combined immunodeficiency (SCID) among the population of the U.S. stood at 355. Moreover, increase in research & development activities and rapid product approvals are projected to fuel the growth of the intravenous immunoglobulin market growth in North America.
Key Developments in Global Intravenous Immunoglobulin Market
Key players in the global intravenous immunoglobulin market are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global intravenous immunoglobulin market are:
Some of the prominent players in the Intravenous Immunoglobulin Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Intravenous Immunoglobulin market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2. Market Share Analysis, by Region, 2017
3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
4. Market Overview
4.1. Indication Overview
4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Rise in prevalence of autoimmune disorders
5.2.2. Increase in global geriatric population
5.2.3. Growing usage in off-label indications
5.2.4. Improved technology for production and purification methods
5.2.5. Favorable government initiatives and approvals
5.2.6. Increase in health care spending & improving health care infrastructure
5.2.7. Rise in incidence of hematological, neurological disorders
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Supply demand gaps
5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5. Opportunities
5.5.1. Application in newer indications
5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.6. Key Trends
5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2030
5.8. Value Chain Analysis
5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook
6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1. Key Findings
6.2. Introduction
6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.4.2. Primary Humoral Immunodeficiency
6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
6.4.4. Guillain-Barre Syndrome
6.4.5. Myasthenia Gravis
6.4.6. Multifocal Motor Neuropathy (MMN)
6.4.7. Kawasaki Disease
6.4.8. Hypogammaglobulinemia
6.4.9. Chronic Lymphocytic Leukemia
6.4.10. Others
6.5. Market Attractiveness Analysis, by Indication
6.6. Key Trends
7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Home Care
7.5. Market Attractiveness Analysis, by End-user
7.6. Key Trends
8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4. Market Attractiveness Analysis, by Region
9. North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Market Analysis, by Indication
9.3.1. Market Value Share Analysis, by Indication
9.3.2. Market Size (US$ Mn) Forecast, by Indication
9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3.2.2. Primary Humoral Immunodeficiency
9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.3.2.4. Guillain-Barre Syndrome
9.3.2.5. Myasthenia Gravis
9.3.2.6. Multifocal Motor Neuropathy (MMN)
9.3.2.7. Kawasaki Disease
9.3.2.8. Hypogammaglobulinemia
9.3.2.9. Chronic Lymphocytic Leukemia
9.3.2.10. Others
9.4. Market Analysis, by End-user
9.4.1. Market Value Share Analysis, by End-user
9.4.2. Market Size (US$ Mn) Forecast, by End-user
9.4.2.1. Hospitals
9.4.2.2. Clinics
9.4.2.3. Home Care
9.5. Market Analysis, by Country
9.5.1. Market Value Share Analysis, by Country
9.5.2. Market Size (US$ Mn) Forecast, by Country, 2017–2030
9.5.2.1. U.S.
9.5.2.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Indication
9.6.2. By End-user
9.6.3. By Country
9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis
9.7.1. Market Size (US$ Mn) Forecast, by Indication
9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.7.1.2. Primary Humoral Immunodeficiency
9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.7.1.4. Guillain-Barre Syndrome
9.7.1.5. Myasthenia Gravis
9.7.1.6. Multifocal Motor Neuropathy (MMN)
9.7.1.7. Kawasaki Disease
9.7.1.8. Hypogammaglobulinemia
9.7.1.9. Chronic Lymphocytic Leukemia
9.7.1.10. Others
9.7.2. Market Size (US$ Mn) Forecast, by End-user
9.7.2.1. Hospitals
9.7.2.2. Clinics
9.7.2.3. Home Care Settings
9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis
9.8.1. Market Size (US$ Mn) Forecast, by Indication
9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.8.1.2. Primary Humoral Immunodeficiency
9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.8.1.4. Guillain-Barre Syndrome
9.8.1.5. Myasthenia Gravis
9.8.1.6. Multifocal Motor Neuropathy (MMN)
9.8.1.7. Kawasaki Disease
9.8.1.8. Hypogammaglobulinemia
9.8.1.9. Chronic Lymphocytic Leukemia
9.8.1.10. Others
9.8.2. Market Size (US$ Mn) Forecast, by End-user
9.8.2.1. Hospitals
9.8.2.2. Clinics
9.8.2.3. Home Care Settings
10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Market Analysis, by Indication
10.3.1. Market Value Share Analysis, by Indication
10.3.2. Market Size (US$ Mn) Forecast, by Indication
10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.3.2.2. Primary Humoral Immunodeficiency
10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.3.2.4. Guillain-Barre Syndrome
10.3.2.5. Myasthenia Gravis
10.3.2.6. Multifocal Motor Neuropathy (MMN)
10.3.2.7. Kawasaki Disease
10.3.2.8. Hypogammaglobulinemia
10.3.2.9. Chronic Lymphocytic Leukemia
10.3.2.10. Others
10.4. Market Analysis, by End-user
10.4.1. Market Value Share Analysis, by End-user
10.4.2. Market Size (US$ Mn) Forecast, by End-user
10.4.2.1. Hospitals
10.4.2.2. Clinics
10.4.2.3. Home Care
10.5. Market Analysis, by Country/Sub-region
10.5.1. Market Value Share Analysis, by Country/Sub-region
10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
10.5.2.1. U.K.
10.5.2.2. Germany
10.5.2.3. France
10.5.2.4. Spain
10.5.2.5. Italy
10.5.2.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis
10.7.1. Market Size (US$ Mn) Forecast, by Indication
10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.7.1.2. Primary Humoral Immunodeficiency
10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.7.1.4. Guillain-Barre Syndrome
10.7.1.5. Myasthenia Gravis
10.7.1.6. Multifocal Motor Neuropathy (MMN)
10.7.1.7. Kawasaki Disease
10.7.1.8. Hypogammaglobulinemia
10.7.1.9. Chronic Lymphocytic Leukemia
10.7.1.10. Others
10.7.2. Market Size (US$ Mn) Forecast, by End-user
10.7.2.1. Hospitals
10.7.2.2. Clinics
10.7.2.3. Home Care Settings
10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis
10.8.1. Market Size (US$ Mn) Forecast, by Indication
10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.8.1.2. Primary Humoral Immunodeficiency
10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.8.1.4. Guillain-Barre Syndrome
10.8.1.5. Myasthenia Gravis
10.8.1.6. Multifocal Motor Neuropathy (MMN)
10.8.1.7. Kawasaki Disease
10.8.1.8. Hypogammaglobulinemia
10.8.1.9. Chronic Lymphocytic Leukemia
10.8.1.10. Others
10.8.2. Market Size (US$ Mn) Forecast, by End-user
10.8.2.1. Hospitals
10.8.2.2. Clinics
10.8.2.3. Home Care Settings
10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis
10.9.1. Market Size (US$ Mn) Forecast, by Indication
10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.9.1.2. Primary Humoral Immunodeficiency
10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.9.1.4. Guillain-Barre Syndrome
10.9.1.5. Myasthenia Gravis
10.9.1.6. Multifocal Motor Neuropathy (MMN)
10.9.1.7. Kawasaki Disease
10.9.1.8. Hypogammaglobulinemia
10.9.1.9. Chronic Lymphocytic Leukemia
10.9.1.10. Others
10.9.2. Market Size (US$ Mn) Forecast, by End-user
10.9.2.1. Hospitals
10.9.2.2. Clinics
10.9.2.3. Home Care Settings
10.10. Spain Intravenous Immunoglobulin (IVIG) Market Analysis
10.10.1. Market Size (US$ Mn) Forecast, by Indication
10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.10.1.2. Primary Humoral Immunodeficiency
10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.10.1.4. Guillain-Barre Syndrome
10.10.1.5. Myasthenia Gravis
10.10.1.6. Multifocal Motor Neuropathy (MMN)
10.10.1.7. Kawasaki Disease
10.10.1.8. Hypogammaglobulinemia
10.10.1.9. Chronic Lymphocytic Leukemia
10.10.1.10. Others
10.10.2. Market Size (US$ Mn) Forecast, by End-user
10.10.2.1. Hospitals
10.10.2.2. Clinics
10.10.2.3. Home Care Settings
10.11. Italy Intravenous Immunoglobulin (IVIG) Market Analysis
10.11.1. Market Size (US$ Mn) Forecast, by Indication
10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.11.1.2. Primary Humoral Immunodeficiency
10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.11.1.4. Guillain-Barre Syndrome
10.11.1.5. Myasthenia Gravis
10.11.1.6. Multifocal Motor Neuropathy (MMN)
10.11.1.7. Kawasaki Disease
10.11.1.8. Hypogammaglobulinemia
10.11.1.9. Chronic Lymphocytic Leukemia
10.11.1.10. Others
10.11.2. Market Size (US$ Mn) Forecast, by End-user
10.11.2.1. Hospitals
10.11.2.2. Clinics
10.11.2.3. Home Care Settings
10.12. Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.12.1. Market Size (US$ Mn) Forecast, by Indication
10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.12.1.2. Primary Humoral Immunodeficiency
10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.12.1.4. Guillain-Barre Syndrome
10.12.1.5. Myasthenia Gravis
10.12.1.6. Multifocal Motor Neuropathy (MMN)
10.12.1.7. Kawasaki Disease
10.12.1.8. Hypogammaglobulinemia
10.12.1.9. Chronic Lymphocytic Leukemia
10.12.1.10. Others
10.12.2. Market Size (US$ Mn) Forecast, by End-user
10.12.2.1. Hospitals
10.12.2.2. Clinics
10.12.2.3. Home Care Settings
11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Market Analysis, by Indication
11.3.1. Market Value Share Analysis, by Indication
11.3.2. Market Size (US$ Mn) Forecast, by Indication
11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.2.2. Primary Humoral Immunodeficiency
11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.3.2.4. Guillain-Barre Syndrome
11.3.2.5. Myasthenia Gravis
11.3.2.6. Multifocal Motor Neuropathy (MMN)
11.3.2.7. Kawasaki Disease
11.3.2.8. Hypogammaglobulinemia
11.3.2.9. Chronic Lymphocytic Leukemia
11.3.2.10. Others
11.4. Market Analysis, by End-user
11.4.1. Market Value Share Analysis, by End-user
11.4.2. Market Size (US$ Mn) Forecast, by End-user
11.4.2.1. Hospitals
11.4.2.2. Clinics
11.4.2.3. Home Care
11.5. Market Analysis, by Country/Sub-region
11.5.1. Market Value Share Analysis, by Country/Sub-region
11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
11.5.2.1. China
11.5.2.2. Japan
11.5.2.3. Australia
11.5.2.4. India
11.5.2.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis
11.7.1. Market Size (US$ Mn) Forecast, by Indication
11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.7.1.2. Primary Humoral Immunodeficiency
11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.7.1.4. Guillain-Barre Syndrome
11.7.1.5. Myasthenia Gravis
11.7.1.6. Multifocal Motor Neuropathy (MMN)
11.7.1.7. Kawasaki Disease
11.7.1.8. Hypogammaglobulinemia
11.7.1.9. Chronic Lymphocytic Leukemia
11.7.1.10. Others
11.7.2. Market Size (US$ Mn) Forecast, by End-user
11.7.2.1. Hospitals
11.7.2.2. Clinics
11.7.2.3. Home Care Settings
11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis
11.8.1. Market Size (US$ Mn) Forecast, by Indication
11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.8.1.2. Primary Humoral Immunodeficiency
11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.8.1.4. Guillain-Barre Syndrome
11.8.1.5. Myasthenia Gravis
11.8.1.6. Multifocal Motor Neuropathy (MMN)
11.8.1.7. Kawasaki Disease
11.8.1.8. Hypogammaglobulinemia
11.8.1.9. Chronic Lymphocytic Leukemia
11.8.1.10. Others
11.8.2. Market Size (US$ Mn) Forecast, by End-user
11.8.2.1. Hospitals
11.8.2.2. Clinics
11.8.2.3. Home Care Settings
11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis
11.9.1. Market Size (US$ Mn) Forecast, by Indication
11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.9.1.2. Primary Humoral Immunodeficiency
11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.9.1.4. Guillain-Barre Syndrome
11.9.1.5. Myasthenia Gravis
11.9.1.6. Multifocal Motor Neuropathy (MMN)
11.9.1.7. Kawasaki Disease
11.9.1.8. Hypogammaglobulinemia
11.9.1.9. Chronic Lymphocytic Leukemia
11.9.1.10. Others
11.9.2. Market Size (US$ Mn) Forecast, by End-user
11.9.2.1. Hospitals
11.9.2.2. Clinics
11.9.2.3. Home Care Settings
11.10. India Intravenous Immunoglobulin (IVIG) Market Analysis
11.10.1. Market Size (US$ Mn) Forecast, by Indication
11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.10.1.2. Primary Humoral Immunodeficiency
11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.10.1.4. Guillain-Barre Syndrome
11.10.1.5. Myasthenia Gravis
11.10.1.6. Multifocal Motor Neuropathy (MMN)
11.10.1.7. Kawasaki Disease
11.10.1.8. Hypogammaglobulinemia
11.10.1.9. Chronic Lymphocytic Leukemia
11.10.1.10. Others
11.10.2. Market Size (US$ Mn) Forecast, by End-user
11.10.2.1. Hospitals
11.10.2.2. Clinics
11.10.2.3. Home Care Settings
11.11. Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.11.1. Market Size (US$ Mn) Forecast, by Indication
11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.11.1.2. Primary Humoral Immunodeficiency
11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.11.1.4. Guillain-Barre Syndrome
11.11.1.5. Myasthenia Gravis
11.11.1.6. Multifocal Motor Neuropathy (MMN)
11.11.1.7. Kawasaki Disease
11.11.1.8. Hypogammaglobulinemia
11.11.1.9. Chronic Lymphocytic Leukemia
11.11.1.10. Others
11.11.2. Market Size (US$ Mn) Forecast, by End-user
11.11.2.1. Hospitals
11.11.2.2. Clinics
11.11.2.3. Home Care Settings
12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Market Analysis, by Indication
12.3.1. Market Value Share Analysis, by Indication
12.3.2. Market Size (US$ Mn) Forecast, by Indication
12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.2.2. Primary Humoral Immunodeficiency
12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.3.2.4. Guillain-Barre Syndrome
12.3.2.5. Myasthenia Gravis
12.3.2.6. Multifocal Motor Neuropathy (MMN)
12.3.2.7. Kawasaki Disease
12.3.2.8. Hypogammaglobulinemia
12.3.2.9. Chronic Lymphocytic Leukemia
12.3.2.10. Others
12.4. Market Analysis, by End-user
12.4.1. Market Value Share Analysis, by End-user
12.4.2. Market Size (US$ Mn) Forecast, by End-user
12.4.2.1. Hospitals
12.4.2.2. Clinics
12.4.2.3. Home Care
12.5. Market Analysis, by Country/Sub-region
12.5.1. Market Value Share Analysis, by Country/Sub-region
12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
12.5.2.1. Brazil
12.5.2.2. Mexico
12.5.2.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis
12.7.1. Market Size (US$ Mn) Forecast, by Indication
12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.7.1.2. Primary Humoral Immunodeficiency
12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.7.1.4. Guillain-Barre Syndrome
12.7.1.5. Myasthenia Gravis
12.7.1.6. Multifocal Motor Neuropathy (MMN)
12.7.1.7. Kawasaki Disease
12.7.1.8. Hypogammaglobulinemia
12.7.1.9. Chronic Lymphocytic Leukemia
12.7.1.10. Others
12.7.2. Market Size (US$ Mn) Forecast, by End-user
12.7.2.1. Hospitals
12.7.2.2. Clinics
12.7.2.3. Home Care Settings
12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis
12.8.1. Market Size (US$ Mn) Forecast, by Indication
12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.8.1.2. Primary Humoral Immunodeficiency
12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.8.1.4. Guillain-Barre Syndrome
12.8.1.5. Myasthenia Gravis
12.8.1.6. Multifocal Motor Neuropathy (MMN)
12.8.1.7. Kawasaki Disease
12.8.1.8. Hypogammaglobulinemia
12.8.1.9. Chronic Lymphocytic Leukemia
12.8.1.10. Others
12.8.2. Market Size (US$ Mn) Forecast, by End-user
12.8.2.1. Hospitals
12.8.2.2. Clinics
12.8.2.3. Home Care Settings
12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.9.1. Market Size (US$ Mn) Forecast, by Indication
12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.9.1.2. Primary Humoral Immunodeficiency
12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.9.1.4. Guillain-Barre Syndrome
12.9.1.5. Myasthenia Gravis
12.9.1.6. Multifocal Motor Neuropathy (MMN)
12.9.1.7. Kawasaki Disease
12.9.1.8. Hypogammaglobulinemia
12.9.1.9. Chronic Lymphocytic Leukemia
12.9.1.10. Others
12.9.2. Market Size (US$ Mn) Forecast, by End-user
12.9.2.1. Hospitals
12.9.2.2. Clinics
12.9.2.3. Home Care Settings
13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Market Analysis, by Indication
13.3.1. Market Value Share Analysis, by Indication
13.3.2. Market Size (US$ Mn) Forecast, by Indication
13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.2.2. Primary Humoral Immunodeficiency
13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.3.2.4. Guillain-Barre Syndrome
13.3.2.5. Myasthenia Gravis
13.3.2.6. Multifocal Motor Neuropathy (MMN)
13.3.2.7. Kawasaki Disease
13.3.2.8. Hypogammaglobulinemia
13.3.2.9. Chronic Lymphocytic Leukemia
13.3.2.10. Others
13.4. Market Analysis, by End-user
13.4.1. Market Value Share Analysis, by End-user
13.4.2. Market Size (US$ Mn) Forecast, by End-user
13.4.2.1. Hospitals
13.4.2.2. Clinics
13.4.2.3. Home Care
13.5. Market Analysis, by Country/Sub-region
13.5.1. Market Value Share Analysis, by Country/Sub-region
13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2030
13.5.2.1. GCC Countries
13.5.2.2. South Africa
13.5.2.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis
13.7.1. Market Size (US$ Mn) Forecast, by Indication
13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.7.1.2. Primary Humoral Immunodeficiency
13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.7.1.4. Guillain-Barre Syndrome
13.7.1.5. Myasthenia Gravis
13.7.1.6. Multifocal Motor Neuropathy (MMN)
13.7.1.7. Kawasaki Disease
13.7.1.8. Hypogammaglobulinemia
13.7.1.9. Chronic Lymphocytic Leukemia
13.7.1.10. Others
13.7.2. Market Size (US$ Mn) Forecast, by End-user
13.7.2.1. Hospitals
13.7.2.2. Clinics
13.7.2.3. Home Care Settings
13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.8.1. Market Size (US$ Mn) Forecast, by Indication
13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.8.1.2. Primary Humoral Immunodeficiency
13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.8.1.4. Guillain-Barre Syndrome
13.8.1.5. Myasthenia Gravis
13.8.1.6. Multifocal Motor Neuropathy (MMN)
13.8.1.7. Kawasaki Disease
13.8.1.8. Hypogammaglobulinemia
13.8.1.9. Chronic Lymphocytic Leukemia
13.8.1.10. Others
13.8.2. Market Size (US$ Mn) Forecast, by End-user
13.8.2.1. Hospitals
13.8.2.2. Clinics
13.8.2.3. Home Care Settings
13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.9.1. Market Size (US$ Mn) Forecast, by Indication
13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.9.1.2. Primary Humoral Immunodeficiency
13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.9.1.4. Guillain-Barre Syndrome
13.9.1.5. Myasthenia Gravis
13.9.1.6. Multifocal Motor Neuropathy (MMN)
13.9.1.7. Kawasaki Disease
13.9.1.8. Hypogammaglobulinemia
13.9.1.9. Chronic Lymphocytic Leukemia
13.9.1.10. Others
13.9.2. Market Size (US$ Mn) Forecast, by End-user
13.9.2.1. Hospitals
13.9.2.2. Clinics
13.9.2.3. Home Care Settings
14. Company Profiles
14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021)
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Baxalta Incorporated
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Biotest AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. China Biologic Products, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. CSL Behring LLC
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Grifols S.A.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Kedrion S.p.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. LFB Biomedicaments S.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Octapharma AG
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sanquin Plasma Products B.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview